NCT03591354 - The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas (DCLP3 Extension) | Biotech Hunter

Enrollment

164

Participants

Timeline

Start Date

January 17, 2019

Primary Completion Date

February 28, 2020

Study Completion Date

March 9, 2020

Conditions

Type 1 Diabetes Mellitus

Interventions

DEVICE

t:slim X2 with Control-IQ Technology & Dexcom G6 CGM

Participants will use the Tandem t:slim X2 insulin pump with Control-IQ Technology \& Dexcom G6 CGM for 3 months.

DEVICE

t:slim X2 with Basal-IQ & Dexcom G6 CGM

Participants will use a Tandem t:slim X2 insulin pump with Basal-IQ and a study CGM (Dexcom G6) for 3 months.

Trial Locations (7)

Icahn School of Medicine at Mount Sinai, New York

University of Virginia Center for Diabetes Technology, Charlottesville

Mayo Clinic, Rochester

Barbara Davis Center, University of Colorado, Aurora

Sansum Diabetes Research Institute, Santa Barbara

Stanford University, Stanford

Harvard University (Joslin Diabetes Center), Boston